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Simple Summary: NSCLC patients with a targetable driver mutation are entitled to receive targeted
therapy. Targeted therapy is usually less toxic than chemotherapy and immunotherapy. However,
low-grade side effects are common and often chronic, which could also negatively impact a patient’s
health-related quality of life (HRQOL). HRQOL in NSCLC patients with and without a targetable
driver mutation is thus likely to be different. To optimize clinical decision making for individualized
treatment in patients with metastatic NSCLC, it is necessary to understand differences in HRQOL
and survival outcomes between patients with and without a targetable driver mutation. In this study,
we show that NSCLC patients with a targetable driver mutation have favorable HRQOL over time
compared to patients without a targetable driver mutation. Furthermore, clinically relevant HRQOL
declines over time were significantly associated with worse survival. HRQOL can therefore play an
important role in shaping patients’ expectations of their prognosis.
Abstract: Background: The aim of this study is to compare long-term health-related quality of life
(HRQOL) and survival in metastatic NSCLC patients with (M+) and without (M−) a targetable
driver mutation. Methods: An observational study was performed within the prospective SYMPRO-
lung study (NL7897). HRQOL questionnaires were completed at baseline, 15 weeks, and 6 months.
Generalized estimating equations (GEE) were used to assess clinically significant declines in HRQOL
(>10 points) over time. Kaplan–Meier survival curves were plotted for both progression-free survival
(PFS) and overall survival (OS). Results: 81 metastatic NSCLC patients were included (M+ patients;
16 (20%)). M+ patients had a significantly better global HRQOL (mean difference 12.8, ES 0.61),
physical functioning (mean difference 13.4, ES 0.63), and less appetite loss (mean difference 23.1,
ES 0.73) at 15 weeks of follow-up compared to M− patients. Patients with a clinically relevant
decline in HRQOL at 6 months of follow-up had a significantly shorter PFS (5 months vs. 12 months,
p-value < 0.001) and OS (11 months vs. 16 months, p-value 0.002). Conclusions: M− NSCLC patients
have less favorable HRQOL over time compared to M+ patients. Furthermore, clinically relevant
HRQOL declines over time were significantly associated with worse survival. HRQOL can therefore
play an important role in in shaping patients’ expectations of their prognosis.
Keywords: non-small cell lung cancer; metastatic lung cancer; health-related quality of life; targetable
driver mutation
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1. Introduction
Lung cancer is the second most commonly diagnosed cancer worldwide, with an
estimated incidence of 2.2 million patients each year. Lung cancer is thereby the leading
cause of cancer-related mortality with 1.8 million deaths yearly [1]. Eighty-four percent of
all lung cancers are non-small cell lung cancer (NSCLC), and of those, half of patients are
diagnosed when metastases are already present [2].
For metastatic NSCLC patients, treatment is aimed at life extension while improving or
at least preserving health-related quality of life (HRQOL). Due to the increased availability
of treatments, especially when a targetable driver mutation is present, treatment decisions
in metastatic NSCLC have become a delicate and complicated process for both the clinician
as well as the patient and their relatives [3,4]. Currently, most clinical decisions are based
on ‘traditional’ clinical criteria, such as mutational status and TNM stage. These clinical
criteria might lead to choosing an inappropriate treatment with severe side effects, even
deteriorating HRQOL during the last phase of life.
NSCLC patients with a targetable driver mutation (M+) are entitled to receive tar-
geted therapy, which has been associated with higher response rates, fewer side effects,
and longer progression-free survival compared to NSCLC patients without a targetable
driver mutation (M−) [5]. Targeted therapy is usually less toxic than chemotherapy and
immunotherapy. However, low-grade side effects are common and often chronic, which
could also negatively impact a patient’s HRQOL [5–8]. HRQOL in NSCLC patients with
and without a targetable driver mutation is thus likely to be different. Although assessing
HRQOL is becoming increasingly important, data on differences in HRQOL in NSCLC
patients with and without a targetable driver mutation are still limited [9].
To optimize clinical decision making for individualized treatment in patients with
metastatic NSCLC, it is necessary to understand differences in HRQOL and survival
outcomes between patients with and without a targetable driver mutation. Therefore,
the aim of this study is to compare long-term HRQOL and survival in metastatic NSCLC
patients with and without a targetable driver mutation.
2. Materials and Methods
2.1. Study Design
The present study was conducted with prospectively collected data from the SYMPRO-
lung study. SYMPRO-lung is a Dutch prospective, multicenter study in which the effect of
online patient-reported outcome symptom monitoring on HRQOL in daily clinical practice
is examined [10]. Monitoring is performed during and after lung cancer treatment. In
short, patients are eligible if they have cytologically/histologically proven or radiologically
suspect small or non-small cell lung cancer, are starting treatment (or a combination)
with radiotherapy, surgery, chemotherapy, immunotherapy, and/or targeted therapy, are
18 years and older, have an Eastern Cooperative Oncology Group (ECOG) performance
status [11] classification of 0, 1 or 2, and have access to the internet. Patients are excluded
if they are already participating in a treatment study that includes structured symptom
reporting, have a life expectancy of less than 15 weeks at time of inclusion, or either
treatment or follow-up of the patient takes place in a center that does not participate in the
study. Patients are still recruited from 3 academic and 11 non-academic hospitals in the
Netherlands and provided informed consent at the start of treatment (up to 2 weeks after
start of treatment). For this study, we included NSCLC patients in the control group with
metastatic lung cancer, who were included between October 2019 and November 2020. The
SYMPRO-lung study was approved by the Medical Ethical Committee (METc) of the VU
University Medical Center in Amsterdam (12 July 2019 Trial NL7897) and is registered on
the Dutch trial register trialregister.nl (Trial NL7897).
2.2. Demographic Characteristics
Demographic characteristics (education, employment status, marital status, and co-
morbidity) are reported by patients at baseline. Clinical data are reported by health care
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practitioners (HCPs) at baseline and include treatment characteristics (ECOG performance
status, histological tumor type, and cancer stage according to the TNM 8th edition and
(previous) treatment). During the follow-up assessments at 15 weeks, 6 and 12 months
after start of treatment, the HCPs are asked to report ECOG performance status, current
treatment, and treatment response (i.e., cured, complete or partial response, stable disease,
progression, relapse, death, and/or other).
2.3. Health-Related Quality of Life
HRQOL questionnaires are completed at baseline, 15 weeks (T1), and 6 months (T2)
after the start of treatment. HRQOL was assessed with the European Organisation for
Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-
C30) [12,13], which includes the overall (global health status and summary score) and
functioning domains (physical functioning, role functioning, cognitive functioning, emo-
tional functioning, and social functioning), and the symptom domains (fatigue, nausea
and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and finan-
cial impact). For each domain, a summary score was calculated according to the EORTC
manual [14]. Additionally, the QLQ-C30 summary score was also calculated as overall
HRQOL by combining the 13 QLQ-C30 scale scores as the mean (excluding financial impact
and a two-item global quality of life scale) [15]. All scores were linearly transformed to
0–100 scales. For the overall and functioning domains, a higher score reflects improved
functioning, while for the symptom domains, a higher score reflects more symptomatology.
Giesinger thresholds for clinical decline were also included to increase the interpretabil-
ity of the QLQ-C30 questionnaire and make it more useful in daily clinical care [16]. A
change of more than 10 points over time was considered a clinically relevant change in
HRQOL [17].
2.4. Data Analysis
Patient characteristics are presented as proportions (for categorical variables) and
mean (±SD) for continuous variables. Differences in baseline characteristics and HRQOL
between patients with and without a targetable driver mutation were compared using inde-
pendent samples t-tests (continuous variables) and chi-square tests (categorical variables).
Generalized estimating equations (GEEs) were used to assess mean change scores in
HRQOL over time between NSCLC patients with and without a targetable driver mutation.
We constructed a model with a random intercept and an unstructured covariance structure.
Improvement of fit of the models was compared based on the maximum likelihood fits.
Differences in mean change scores over time between groups were interpreted with Cohen’s
effect size (ES) [18]. An ES of 0.20 was considered small, 0.50 moderate and clinically
significant, and 0.80 large [19].
Overall survival was defined as time from start of treatment to time of death from
any cause, or to time of last follow-up (censoring). Progression-free survival (PFS) was
defined as time from start of treatment until disease progression, tumor recurrence, or
death from any cause. Cumulative incidence, 6-month, and 1-year mortality rates were
investigated. Kaplan–Meier survival curves stratified for mutation status and clinically
significant declines in HRQOL were plotted for both PFS and OS. All analyses were




In total, 81 patients were included in this study, of whom 16 (20%) had a targetable
driver mutation. Median follow-up duration was 15 months (IQR 11 to 17 months) with
no difference between patients with and without a targetable driver mutation (16 vs.
15 months, respectively).
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3.2. Baseline Characteristics
Table 1 shows baseline characteristics for the total study population and stratified for
NSCLC patients with and without a targetable driver mutation. Mean age was 65.1 years
and half of the patients (50.6%) were men. Most patients presented with ECOG perfor-
mance status of 0 (33.3%) or 1 (59.3%) at baseline. Almost half of patients (44%) with a
targetable driver mutation were treated with targeted therapy, whereas patients without a
targetable driver mutation were most often treated with a combination of radiotherapy plus
immunotherapy (43%). Except for molecular analysis and treatment, no further significant
differences in baseline characteristics between the two patient groups were observed. M+
patients who received targeted therapy had a slightly better performance score compared
to M− patients and M+ patients who did not receive targeted therapy. Furthermore, there
were no significant differences between patients receiving targeted therapy and those who
did not (Table S1).
Table 1. Baseline characteristics.
Characteristics Total StudyPopulation NSCLC M+ NSCLC M− p-Value
Total 81 16 65
Age (years) 65.11 (9.46) 68.13 (10.21) 64.37 (9.20) 0.156
Gender (% male) 41 (50.6%) 6 (37.5%) 35 (53.8%) 0.276
ECOG Performance Status 0.142
0 27 (33.3%) 4 (25%) 23 (35.4%)
1 48 (59.3%) 9 (56.3%) 39 (60%)
2 6 (7.4%) 3 (18.8%) 3 (4.6%)
Comorbidities
Yes (%) 31 (38.3%) 7 (43.8%) 24 (36.9%) 0.775
Histology <0.001
Adenocarcinoma, mutation
unknown 16 (19.8%) - 16 (24.6%)
Adenocarcinoma, M− 33 (40.7%) - 33 (50.8%)
Adenocarcinoma, M+ 16 (19.8%) 16 (100%)
Squamous cell carcinoma 10 (12.3%) - 10 (15.4%)
Large cell carcinoma 6 (7.4%) - 6 (9.2%)
Treatment plan <0.001
Immunotherapy 24 (29.6%) 3 (18.8%) 21 (32.3%)
Immunotherapy combined 32 (39.5%) 4 (25%) 28 (43.1%)
Radiotherapy 5 (6.2%) 1 (6.3%) 4 (6.2%)
Chemotherapy combined 13 (16%) 1 (6.3%) 12 (18.5%)
Targeted therapy 7 (8.6%) 7 (43.8%) -
Age is presented as mean (SD) and as n (%), other data are presented as n (%). Abbreviations: NSCLC, non-small
cell lung cancer; M+, targetable driver mutation; ECOG, Eastern Cooperative Oncology Group.
3.3. Health-Related Quality of Life
Table 2 shows mean HRQOL values at baseline, 15 weeks, and 6 months of follow-up.
At baseline, no significant differences in HRQOL between patients with and without a
targetable driver mutation were observed. During follow-up, patients with a targetable
driver mutation had significantly better overall HRQOL and social functioning compared
to patients without a targetable driver mutation. Furthermore, patients with a targetable
driver mutation had significantly less complaints of dyspnea, fatigue, nausea and vomiting,
and constipation during follow-up (Table 2).
Cancers 2021, 13, 4282 5 of 10
Table 2. Mean Health-Related Quality of Life scores.
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Scores indicate means (SD). EORTC Quality of life score and functioning domains: higher score = better QOL/functioning. EORTC
Symptom Domains: higher score = worse symptoms. Abbreviations: T0, baseline; T1, 15 weeks; T2, 6 months; NSCLC, non-small cell lung
cancer; M+, targetable driver mutation; * indicates significant differences (p-value < 0.05) between the M− and M+ group.
After adjustment for treatment, clinically relevant between-group differences in mean
change scores over time were found for global HRQOL, physical functioning, and appetite
loss (Table 3). At 15 weeks of follow-up, patients with a driver mutation had signifi-
cantly better global HRQOL (mean difference 12.8, ES 0.61), physical functioning (mean
difference 13.4, ES 0.63), and less appetite loss (mean difference 23.1, ES 0.73) compared
to patients without a targetable driver mutation. Although HRQOL almost restored at
6 months of follow-up across all domains, patients with a driver mutation still showed
significantly better physical functioning (mean difference 9.5, ES 0.45) and less appetite loss
(mean difference 14.3, ES 0.45) compared to patients without a targetable driver mutation.
No significant differences between the groups over time for the other HRQOL domains
were observed.
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Table 3. Between-group differences in Health-Related Quality of Life between baseline to follow-up.







Global Quality of Life
NSCLC M− (ref; M+) −12.8 (20.9) 0.61 −5.9 (20.9) 0.28
Physical Functioning
NSCLC M− (ref; M+) −13.4 (21.3) 0.63 −9.5 (21.4) 0.45
Appetite loss
NSCLC M− (ref; M+) 23.1 (31.8) 0.73 14.3 (31.2) 0.45
Scores are presented as mean change scores from baseline between groups, with NSCLC M+ as reference group.
Abbreviations: T0, baseline; T1, 15 weeks; T2, 6 months; SE, standard error; ES, effect size; NSCLC, non-small cell
lung cancer; M+, targetable driver mutation.
3.4. Survival
Table 4 shows OS rates and Figure 1 shows the Kaplan–Meier OS curve for the two
groups. During follow-up, 28 (35%) patients died, which was not significantly different
across the two patient groups. Mean OS was 14 months, not significantly different between
the two groups (Table 4). Although non-significant, a trend towards better 12-month
survival rates for patients with a targetable driver mutation compared to patients without
a targetable driver mutation was observed (7% vs. 39%, p-value 0.074, respectively). No
differences in PFS were observed.
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Table 4. Mortality rates.
Time Point Total StudyPopulation NSCLC M− NSCLC M+ p-Value
Total 81 (100%) 65 (80%) 16 (20%) -
Total mortality 28 (35%) 25 (39%) 3 (11%) 0.240
6-month mortality (%) 17 (21%) 16 (25%) 1 (6%) 0.171
12-month mortality (%) 27 (33%) 25 (39%) 2 (7%) 0.074
Mean OS time (SE) 14.2 (0.75) 13.1 (0.79) 16.6 (1.3) 0.140
Data are presented as n (%). Abbreviations: NSCLC, non-small cell lung cancer; M+, targetable driver mutation;
OS, overall survival; SE, standard error.
3.5. HRQOL Decline
Since no significant differences in OS and PFS between the groups were observed,
prognostic analyses for HRQOL declines on OS and PFS were performed for the entire
patient group. At 6 months of follow-up, a clinically relevant decline (>10 points) in
HRQOL (defined by the summary score) was significantly associated with both OS as
well as PFS. Patients with a significant decline in HRQOL at 6 months of follow-up had a
significantly shorter PFS (5 months vs. 12 months, p-value < 0.001) as well as a significantly
shorter OS (11 months vs. 16 months, p-value 0.002).
4. Discussion
In this observational study of stage IV NSCLC patients, we found that patients with
a targetable driver mutation had better HRQOL over time compared to NSCLC patients
without a targetable driver mutation. Since we also observed a tendency towards favor-
able survival rates in patients with a targetable driver mutation, these patients are more
likely to live longer with a better quality of life compared to those without a targetable
driver mutation.
To our knowledge, this is the first observational study comparing HRQOL over
time in stage IV NSCLC patients with and without a targetable driver mutation. An
improved HRQOL in patients with a targetable driver mutation may not be surprising,
given the improved HRQOL rates in targeted therapy trials [20,21]. Both survival rates and
HRQOL may improve for the whole population of patients with lung cancer because of
advancements in treatment options. An example is the addition of Metformin to treatment,
a standard antidiabetic agent that shows promising results [22]. Nonetheless, not all
patients with a targetable driver mutation received targeted therapy in this study (Table 1).
Furthermore, even after correction for treatment, we observed better HRQOL over time
in NSCLC patients with a targetable driver mutation compared to patients without a
targetable driver mutation. Apart from less severe side effects, it could be that patients
with a targetable driver mutation have less anxiety regarding their prognosis because their
doctors may frame their mutation as relatively good news, resulting in favorable HRQOL
over time [23]. Nonetheless, more research is needed to elucidate the mechanism behind
the observed HRQOL benefit.
We did not observe differences in patient characteristics between patients with and
without a targetable driver mutation. From the literature, we know that patients with a
targetable driver mutation are more often younger, female, never-smokers, and of Asian
ethnicity [24]. Although non-significant, patients with a targetable driver mutation in our
study population were indeed slightly younger and more often female. Unfortunately, we
did not have information on ethnicity or smoking history and can therefore not confirm
the reported association between ethnicity, smoking, and mutational status.
In the total study population, patients with a clinically relevant decline in HRQOL
over time had worse PFS and OS. This finding indicates that HRQOL in general is very
important when it comes to individualized clinical decision making in stage IV NSCLC
patients, regardless of their mutational status. For these patients, treatment is aimed at
life extension while improving HRQOL. We recently found that pre-treatment HRQOL
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goals are only met by less than half of patients [3,4]. In addition, patients with an incurable
disease often have a poor prognostic perception, as a result of the efficacy–effectiveness
gap [25], (which can increase) deficient patient–doctor communication, as well as attempts
of patients and their relatives to maintain the hope of a cure. Our results underline even
more that taking HRQOL into account is essential to optimize clinical decision making for
individualized treatment and thereby improve or at least maintain HRQOL in patients
with stage IV NSCLC.
Strengths of this study include its novel focus on HRQOL over time in patients
with and without a targetable driver mutation and the association of HRQOL declines
with survival outcomes. There are also some limitations to our study. Because of the
observational nature of the study design, no causal relationships can be distinguished.
We had no information on cause-specific mortality and mutation type. Therefore, we
cannot elucidate whether mortality was NSCLC-specific. Lastly, although our results are
promising, the sample size was quite small and strict selection criteria were handled due to
the study design. Therefore, our results might not be generalizable to ‘real world’ stage IV
NSCLC patients who are generally older, and have a worse performance score and more
comorbidities, including COPD, which may limit applicability of therapies.
5. Conclusions
In conclusion, our findings indicate that stage IV NSCLC patients with a targetable
driver mutation have favorable HRQOL over time compared to stage IV NSCLC patients
without a targetable driver mutation. Furthermore, clinically relevant HRQOL declines
over time were significantly associated with worse survival, regardless of mutational status.
These results indicate that HRQOL can play a potentially important role in clinical decision
making and in shaping the patient’s expectations of prognosis. In addition, it can be of
importance in individual risk stratification and tailored supportive follow-up care.
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